Sutro Biopharma to Participate in Multiple Investor Conferences
News related to:Sutro Biopharma · 1 min read
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 /CourierPR/ -- Sutro Biopharma, a clinical-stage oncology company, is set to participate in several upcoming investor conferences, providing updates on its innovative antibody drug conjugate (ADC) platform and pipeline.
The company will host a fireside chat at the Stifel Healthcare Conference on November 11 at 8:00 AM Eastern Standard Time (EST) in New York, NY. This event will offer investors a chance to hear directly from Sutro Biopharma’s management team about the company’s progress and future plans.
On November 12, Sutro Biopharma will participate in the Truist Securities Biopharma Symposium, also held in New York, NY. While the specific timing is not provided, the company will be present to discuss its advancements and strategies.
Sutro Biopharma will also present at the UBS Global Biopharma Conference on November 17 at 10:40 AM Greenwich Mean Time (GMT) in London, UK. This session will likely cover the company’s latest research and development activities, as well as its dual-payload ADCs designed to improve drug exposure and reduce side effects.
Another key event for Sutro Biopharma is the Jefferies Global Healthcare Conference, where the company will host a fireside chat on November 18 at 1:30 PM GMT in London, UK. This session will provide further insights into the company’s pipeline and its approach to addressing unmet needs in cancer therapy.
Lastly, Sutro Biopharma will participate in the Piper Sandler 38th Annual Healthcare Conference, with a fireside chat scheduled for December 2 at 1:30 PM EST in New York, NY. The company will use this platform to engage with investors and share its vision for the future.
Sutro Biopharma’s focus on developing next-generation ADCs aims to deliver breakthroughs for patients with cancer by optimizing the antibody, linker, and payload. The company’s dual-payload ADCs are particularly noteworthy, as they are designed to overcome treatment resistance and expand the range of treatable tumor types.